Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
AstraZeneca
Hoffmann-La Roche
Wake Forest University Health Sciences
EMD Serono
M.D. Anderson Cancer Center
University of California, San Diego
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Boehringer Ingelheim
Radiation Therapy Oncology Group
Boehringer Ingelheim
Eli Lilly and Company
Varian, a Siemens Healthineers Company
I-Mab Biopharma US Limited
University of Colorado, Denver
Incyte Corporation
Dana-Farber Cancer Institute
Tempus AI
University of Kentucky
University of Arkansas
Sanford Health
EMD Serono
University of Pennsylvania
Massachusetts General Hospital
University of Wisconsin, Madison
Merck Sharp & Dohme LLC
Palleon Pharmaceuticals, Inc.
Incyte Corporation
MacroGenics
The University of Texas Health Science Center at San Antonio
Incyte Corporation
GERCOR - Multidisciplinary Oncology Cooperative Group
Icahn School of Medicine at Mount Sinai
University of California, San Diego
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Medical College of Wisconsin
University of California, San Diego
University of Colorado, Denver
Hoffmann-La Roche
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals
Alume Biosciences, Inc.
VA Office of Research and Development
Thomas Jefferson University
M.D. Anderson Cancer Center
Elevation Oncology
GeoVax, Inc.